Rongchang Pharmaceutical was founded in 1993 and is headquartered in Yantai, China. It is a company integrating R&D, production, sales and services, spanning modern Chinese medicine, small molecule and biopharmaceuticals, biopharmaceutical research and development and production services (CDMO), biopharmaceutical enterprise and Project incubation of modern pharmaceutical companies in four major fields.

Rongchang Pharmaceutical and its subsidiaries have a total of 94 drug production approval numbers and 70 patents, mainly Chinese patent medicines.

Since its establishment, the company has always been committed to the development and application of traditional Chinese medicine modernization. The leading product, "Antai", is the crystallization of the modernization of traditional Chinese medicine. Based on traditional Chinese medicine theory, it introduces concentrated, transdermal, sustained release and patches. Four high-tech technologies have created the method of "adding the belly button to treat hemorrhoids". Later, the drug "Sweet Dream" series of calming the mind, the drug "Kunning Oral Liquid" that regulates dysfunctional uterine bleeding, the drug "Yuetai Paste Umbilical Tablet" that relieves primary dysmenorrhea, and the new drug Bisacodine for constipation More than ten products including Shuan (Xietai), Motedin Chewable Tablets (Shiwei) for Gastric Diseases.

While developing the modernization of traditional Chinese medicine and achieving outstanding achievements, the company has entered the field of bioengineering technology and has become one of the more active enterprises on the biotechnology stage in my country. In June 1999, the company cooperated with the American PhD team to conduct bioengineering technology research, and in 2005, it successfully developed a new anti-tumor drug, recombinant human vascular endostatin "YH-16" (trade name: Endu) . The launch of this drug marks that China is at the forefront of the world in the research and development of anti-tumor drugs in vascular inhibitors; in May 2008, it cooperated with the team of a doctoral student in the United States to establish Yantai Rongchang Bioengineering Co., Ltd., which is mainly engaged in immunosuppressants The research and development of the "Taiai" project, a new drug for genetic engineering, will provide new solutions for patients with autoimmune system diseases and B lymphocyte tumors after the project is completed. After the product is launched into an industrial scale, it will have high development and application value and Broad market prospects.

Rongchang Pharmaceutical focuses on traditional business segments, "inheriting the essence, adhering to the truth and innovation", takes Chinese patent medicine business as the main direction, and scientific and technological innovation as a breakthrough point, and expands in depth through capital and technology promotion to achieve grand strategic goals.